Recognized T-cell acute lymphoblastic leukemias (T-ALLs) oncogenic pathways include transcriptional deregulation of oncogenes by juxtapositioning to the T-cell receptor b (TCRB) or a/d (TCRA/D) enhancer loci, resulting in overexpression of genes such as LMO2, LMO1, LYL1, TAL1/SCL, and homeodomain genes such as TLX1/HOX11, TLX3/HOX11L2 or HOXA. A V(D)J error-type mechanism has been proposed to explain such recurrent chromosomal events but other processes are likely to intervene, particularly those mediating the chromosomal break at the locus bearing the proto-oncogene. 1 Evidence in favor of V(D)J-mediated errors include the presence of non-templated nucleotides (n-diversity) at the chromosomal junction and of recognition signal sequences (RSS) or RSS-like sequences at the vicinity of the breakpoints on the derivative chromosomes, although putative RSS-like sequences are usually incomplete.
The HOXA gene cluster on chromosome 7p15 has recently been described as a new recurrent TCRB partner in T-ALL. 2, 3 In cases with TCRB-HOXA translocation, a variable but consistent combination of individual HOXA genes on both sides of the breakpoint appears to be upregulated. The juxtapositioning of TCRB enhancer elements and the HOXA locus disruption in itself might deregulate the whole cluster expression. In other cases, trans-regulating factors can deregulate the whole HOXA cluster. The MLL protein directly regulates HOX family genes 4 and chimeric MLL oncoproteins are recognized to mediate HOX deregulation in AML and B-and T-lineage ALL. 5 T-cell acute lymphoblastic leukemia with CALM-AF10 fusions also demonstrate HOXA cluster upregulation, 2, 6 but the mechanisms mediating gene deregulation in these cases remain to be explored.
We here describe cytogenetic and molecular findings in the first case of T-ALL with both CALM-AF10 and a t(7;14)(p15;q11), juxtaposing the HOXA cluster to the TCRD Jd1 gene segment.
A 29-year-old male patient with hepatosplenomegaly but no mediastinal involvement was diagnosed with T-ALL at Purpan Hospital (Toulouse, France). White blood cell count was 42 Â 10 9 /l. Immunophenotyping and real time quantitativepolymerase chain reaction (RQ-PCR) revealed a TCRgd þ , CD4/8 double positive, CD1a-phenotype expressing high levels of RAG-1 and pre-T-cell receptor alpha (PTCRA) transcripts, previously reported as UPN 3749. 7 Karyotype analysis showed 46,XY, t(7;14)(p15;q11),t(10;11)(p13-14;q14-21),add(18)(q23)
[11]/46,XY [9] . RT-PCR analysis revealed the presence of a CALM-AF10 fusion as predicted by the t(10;11)(p14;q21). 7 Southern blot analysis of DNA extracted from a bone marrow sample at diagnosis revealed two rearranged BglII-digested Jd1 fragments (data not shown). Multiplex TCRD PCR showed one clonal Vd1-Jd1 rearrangement but the second rearranged allele was not identified, and as such did not correspond to a classical TCRD rearrangement.
PvuII digestion and Jd1 amplification by ligation-mediatedpolymerase chain reaction (LM-PCR) generated a product of approximately 350 bp (Figure 1a ), which on sequencing was shown to contain a Jd1-HOXA junction, with the intact start of Jd1 separated by nine n-diversity nucleotides from an intronic fragment of chromosome 7, located between the HOXA6 and HOXA7 genes. A specifically designed PCR confirmed the breakpoint sequence (Figure 1b) .
To search for the derivative breakpoints, the ligated PvuIIdigested DNA was amplified with the Der(14)S-specific primer, corresponding to the translocated telomeric part of chromosome 7. Two fragments of 600 and 700 bp were obtained (Figure 1c) . Sequencing revealed that the 600 bp fragment corresponded to the genomic sequence of chromosome 7, whereas the 700 bp fragment showed chromosome 7 rearranged with the dREC1 segment on chromosome 14. A specifically designed primer pair confirmed the junction (Figure 1b) and revealed that the leukemic clone had already undergone Dd2-Dd3 rearrangement. (a) Run of DraI and PvuII-digested LM-PCR product using the Jd1-specific primer. The t(7;14) junction was amplified from the PvuIIdigested fragment appearing around 350 bp. The other DraI-digested product of interest measuring around 1 kb represents the Vd1-Jd1 rearrangement of the second allele. The two products for the DraI and PvuII digestions appearing around 450 and 900 bp represent the expected germline products of 458 and 827 bp, respectively, amplified from the background population. (b) Direct PCR designed to amplify the der (7) and (14) junctions showing products of expected length. (c) Run of PvuII-digested LM-PCR product using the DerS specific primer. The 600 bp product corresponds to the genomic chromosome 7 sequence. The 700 bp product corresponds to the der(14).
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The translocation was balanced, with loss of only a single nucleotide from chromosome 7 ( Figure 2 ). The dREC-chromosome 7 translocation most probably happened during attempted Dd3-Jd1 joining ( Figure 3 ). The addition of n-nucleotides at the junctions is compatible with a V(D)J error-type translocation mechanism. However, the heptamer-like sequence in the vicinity of the der(7) breakpoint diverges from the consensus heptamer sequence.
This case is of particular interest as it represents the first description of a TCRD-HOXA translocation, as all nine previously reported cases of T-ALL with HOXA cluster translocations involved the TCRB locus. The HOXA breakpoint between HOXA6 and HOXA7 in the present case is telomeric to the four TCRB-HOXA cases, which clustered in a 2.6-kb region between HOXA10 and HOXA9, 2 and to the three additional TCRB-HOXA cases where the breakpoint was clustered in intron 1A of the HOXA9 gene locus (Cauwelier et al., unpublished data). The relative incidence of TCRB and TCRD-HOXA translocations needs to be tested by Fluorescence in situ hybridisation (FISH), as TCRB-HOXA translocations are difficult to detect on classical caryotyping. The localization of the TCRD and HOXA loci makes cryptic t(7;14)(p15;q11) unlikely if mitosis is representative of the leukemic clone.
As for other TCR translocations, to what extent TCR-HOXA rearrangements represent V(D)J errors is not yet clear. Soulier et al. described two heptamer-like sequences beside the HOXA breakpoints on the derivative chromosome 7. In our case, junctional diversity at the der(7) junction and at the dRec-Dd2-Dd3 junction on the der(14) is in keeping with RAG-induced events. However, the heptamer-like sequence 5 0 to the breakpoint on chromosome 7 is not concensus (underscored in Figure 2 ). It can therefore be postulated that the strand break on chromosome 14 and the illegitimate ligation to chromosome 7 are RAG-induced, whereas the mechanism initiating the break Figure 2 The nucleotide sequence of both derivatives implicated in the t(7;14) translocation. Underscored are recognition signal sequences (RSS) or RSS-like sequences in the vincinity of the breakpoints. Lowercase letters denote non-templated nucleotides at the junction.
Figure 3
Sequence of events leading to the final translocation. Exons are represented by boxes. Triangles represent recognition signal sequences and show their orientation. E ¼ enhancer.
Letters to the Editor on chromosome 7 remains to be defined. Although illegitimate V(D)J recombination has been proposed to be involved in most Ig/TCR-proto-oncogene recurrent lymphoid translocations, functional models do not always support this assumption and suggest that for certain recurrent translocations the breaks at the non-immune locus are initiated by other, as yet unknown, mechanisms. 1 The present case is likely to belong to this category.
As expected, FISH analysis confirmed the colocalization of TCRD and HOXA probes in six of eight mitosis and in 80% of interphase nuclei. The CALM-AF10 translocation was confirmed by FISH in more than 80% of interphase nuclei, thus demonstrating the existence of the two translocations in the vast majority of cells and excluding the possibility of two distinct clones (Figure 4a and b) , in accordance with the karyotype showing both translocations in 11 mitosis. Given that CALM-AF10 þ T-ALL overexpress HOXA genes, 2, 6 albeit by an unknown mechanism, it was surprising to find another HOXA genetic abnormality in the same leukemic clone.
We therefore analyzed HOXA transcript levels in order to assess the relative impact of CALM-AF10 and TCRD-HOXA on HOXA overexpression. We compared transcript expression of the whole HOXA cluster in this case to a series of 12 other CALM-AF10 þ T-ALL with no evident karyotypic abnormalities involving chromosome band 7p15 ( Figure 5 ). As expected, HOXA cluster genes were overexpressed although the presence of the HOXA-TCRD translocation did not give rise to a clearly distinct pattern of HOXA gene expression in comparison to CALM-AF10 þ T-ALL without apparent TCRD-HOXA rearrangement, in particular with respect to the HOXA6 and HOXA7 genes adjacent to the breakpoints. This would suggest that rupture of the HOXA locus by TCRD is sufficient to lead to generalized HOXA deregulation on both sides of the breakpoint, not restricted to the genes adjacent to the breakpoint, as previously described for HOXA-TCRB.
2 HOXA expression may therefore be deregulated by elements other than the TCRD (or TCRB) enhancers. Alternatively, as this case also demonstrates a CALM-AF10 fusion, the HOXA profile may be determined in this case by CALM-AF10 rather than HOXA-TCRD, thus explaining the absence of distinct HOXA profiles when compared with 'isolated CALM-AF10' T-ALLs. This is compatible with a predominant trans-mediated influence of CALM-AF10 on HOXA deregulation, which a cis-mediated effect of the TCRD-HOXA6/7 juxtaposition does not over-ride.
This case expressed both a surface TCRgd receptor and PTCRA, which is normally restricted to the TCRab lineage. We have previously shown that TCRgd þ PTCRA þ T-ALLs often demonstrate deregulation of orphan homeobox-like genes (HOX11/TLX1 or HOX11L2/TLX3) 8 and that these cases are characterized by high RAG-1 levels, which suggest active, but unproductive V(D)J activity with respect to a complete TCR. Such a scenario is conducive to V(D)J errors, as described here for the dRec-Jd-HOXA rearrangement identified in the majority of the leukemic clone.
In conclusion, we report that HOXA deregulation by TCR juxtapositioning is not restricted to TCRB, with impact for screening practice. The coexistence of HOXA-TCRD and CALM-AF10 in this case does not modify the HOXA deregulation profile observed in CALM-AF10 T-ALLs. This would suggest a dominant trans-mediated mechanism of HOXA deregulation by CALM-AF10, which merits to be explorated.
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This work was supported by the Fondation contre la leucémie de la Fondation de France and Association de Recherche sur le Cancer (ARC). RQ-PCR quantification of the HOXA transcripts. Absolute DC t (cycle threshold) value ¼ TBP C t ÀHOXA C t . Particular subtypes of acute myeloid leukemia (AML)s and myelodysplastic syndromes (MDS) are associated with specific recurrent chromosomal anomalies. Among these are translocations involving 21q22, which are commonly observed in both de novo and therapy-related (t-)MDS and AML. The t(8;21)(q22;q22), t(3;21)(q26;q22) and t(16;21)(q24;q22) are most frequently observed, but other variants have been described as well. 1, 2 The majority of these translocations result in a fusion of the 5 0 region of the RUNX1 (CBFA2, AML1) gene with the 3 0 region of either one of its partner genes. 1 Here, we report a patient with therapy-related AML and a rare t(1;21)(p36;q22). 3 0 RACE experiments followed by sequencespecific RT-PCR resulted in the identification of the PRDM16 gene as a novel fusion partner of the RUNX1 gene in this patient.
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A 47-year-old woman was referred to our hospital with pancytopenia in 2002. In 1999, she had been diagnosed elsewhere with invasive breast cancer and positive axillary lymph nodes without distant metastases, for which she was treated with mastectomy, adjuvant radiotherapy, chemotherapy and tamoxifen. Hematologic examination showed white blood cells (WBC) of 1.1 Â 10 9 /l with 43% polymorphonuclear cells (PMN's), hemoglobin level of 7.0 mmol/l and a platelet count of 42 Â 10 9 /l. Bone marrow biopsy showed hypoplastic bone marrow with severe myelodysplasia. Bone marrow karyotypes were obtained after short-term cultures, chromosomes were GTG-banded and the karyotype was described according to the International System for Human Cytogenetic Nomenclature (Figure 1, right panel) . As normal female karyotype was found at diagnosis, these chromosomes were evaluated. Owing to the lack of quality of the metaphases and lack of suitable material for FISH analysis, we cannot exclude the possibility that the cryptic translocation t(1;21)(p36;q22) was missed at diagnosis. In July 2005, bone marrow examination revealed an acute myelomonocytic leukemia and a 46,XX,t(1;21)(p36;q22),del(7)(q?34) [7] /47,idem, þ 13 [3] karyotype. The patient died a few months later. An extensive literature search through Medline (http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi) and the Mittelman Database of Chromosome Aberrations in Cancer (http://cgap.nci.nih.gov/Chromosomes/Mitelman) revealed four additional cases (Table 1 ). This turns the t(1;21)(p36;q22) into a rare but recurrent translocation. The t(1;21)(p36;q22) seems to be associated with a relatively short survival time (6-7 months). (Partial) loss of chromosome 7 was observed in case 2 and in the present case during relapse. Although only present in two cases, it should be noted that chromosome 7 abnormalities are the most commonly observed secondary changes in patients with other 21q22 translocations. 1 Two cases were therapy-related and had treatment histories that included topoisomerase II targeting agents. This observation
